Navigation Links
Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
Date:12/8/2008

h chronic hepatitis C. Hepatitis C virus can cause serious liver disease, leading to cirrhosis, primary liver cancer and even death.

Conference Call

HGS management will hold a conference call to discuss this announcement today at 8:15 AM Eastern. Investors may listen to the call by dialing 888-215-6982 or 913-312-0389, passcode 7154642, five to 10 minutes before the start of the call. A replay of the conference call will be available within a few hours after the call ends. Investors may listen to the replay by dialing 888-203-1112 or 719- 457-0820, confirmation code 7154642. Today's conference call also will be webcast and can be accessed at www.hgsi.com. Investors interested in listening to the live webcast should log on before the conference call begins to download any software required. Both the audio replay and the archive of the conference call webcast will remain available for several days.

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing.

ABthrax(TM) (raxibacumab) is in late-stage development for the treatment of inhalation anthrax, and the Company is awaiting authorization to begin the delivery of 20,000 doses of ABthrax to the Strategic National Stockpile under a contract entered into with the U.S. Government in June 2006. HGS also has three drugs in clinical development for the treatment o
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... ... Inc. Magazine released its annual list of the 5,000 fastest-growing privately held ... the three years through 2014. Being named to the Inc. 5000 list designates a ... , “We are thrilled to make the Inc. 5000 list for 2015,” stated ...
(Date:8/26/2015)... KS (PRWEB) , ... August 26, 2015 , ... ... Biologic Solutions, announces today that a second US laboratory is to open in ... accordance with the continued partnership and long-term growth of research and development through ...
(Date:8/26/2015)... -- The Diabetes Research Institute (DRI), a Center of ... of Medicine, announced today that the first patient ... first time a novel transplant technique for insulin-producing ... I/II study builds upon decades of progress in ... step toward the development of the DRI BioHub, ...
(Date:8/26/2015)... China Cord Blood Corporation (NYSE: CO ... provider of cord blood collection, laboratory testing, hematopoietic stem ... that the Company has been informed that Magnum Opus ... by Mr. Yuen Kam, chairman of the board of ... (the "Shares") of  Excellent China Healthcare Investment Limited ("KKR ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3
... dr. Stuart Parkin as its first ,distinguished professor, ever. Parkin ... of the IBM Almaden Research Center in the USA. Earlier ... Parkin is an expert in the field of spintronics. , ... international top professor to be appointed to this position for ...
... IDIX ) announced today that it will report,its ... Thursday, October,30, 2008 after the U.S. financial markets close., ... release, Idenix,management will host a conference call at 4:30 ... company,s financial results for the third quarter,of 2008 and ...
... Our Children Foundation,a nonprofit charitable foundation dedicated to ... Administration (FDA) has approved the Orphan,Drug Designation of ... Sarcoma cancer. The efforts to develop this drug ... in private industry and at two,universities., Orphan ...
Cached Biology Technology:FDA Approves Orphan Drug Status for Revolutionary Cancer Drug for Children 2
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, featuring FPC,s touch ... 2015 that relate to sales of FPC1155 for this smartphone model ... for 2015. Jörgen Lantto, CEO of FPC, comments: " ... manufacturer in China and we are proud ... for Z1 , its first ...
(Date:8/6/2015)... Aug. 6, 2015  Today, U.S. Congressman ... Crossmatch ™ to learn firsthand how Silicon Valley ... Crossmatch is a world leader in multi-factor identity ... are helping federal agencies and commercial organizations achieve ... "The vast majority of network breaches ...
(Date:8/5/2015)... , August 5, 2015 ... & Access Management Market by Software, Services, Vertical (BFSI, Airport, ... & Geography - Global Forecast to 2020", published by ... Management Market globally into various segments. The global PIAM ... 2014 to $546.2 Million by 2019, at a CAGR ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Rep. Honda to Visit Crossmatch in Redwood City 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... Something,s up with the weather in Namibia, say geoscientists ... Paul Bierman of the University of Vermont in Burlington, Vt. ... the western mountains and coastal plain of this sparsely populated ... where the stream beds are sand and the "lakes" are ...
... New research aimed at controlling the transmission of diseases ... made possible by grants from a collaboration among U.S. ... of the factors affecting disease transmission, the projects will ... Funding is from the U.S. National Science Foundation (NSF) ...
... 2011 Science in Society Journalism Awards, sponsored by the National ... Book category, Maryn McKenna for her book Superbug: The Fatal ... Reporting category, Katy Butler for her New York Times Magazine ... Reporting for a Local or Regional Audience category, Barbara Moran ...
Cached Biology News:Something odd is happening with Namibia's weather 2Something odd is happening with Namibia's weather 3Investigating the spread of infectious diseases with NSF, NIH, UK funding 2Investigating the spread of infectious diseases with NSF, NIH, UK funding 3Investigating the spread of infectious diseases with NSF, NIH, UK funding 4Investigating the spread of infectious diseases with NSF, NIH, UK funding 52011 Science in Society Awards announced 22011 Science in Society Awards announced 3
... matrix for the extraction of unwanted ... other macromolecules, Applications: ,Reducing octyl glucoside ... interaction of pure β-adrenergic receptor and ... SDS in 6 M urea/0.05 mM ...
... cells form from a hematopoietic stem cells ... to the bone surface and lowering the ... around 4.5. The bone mineral is then ... and function is controlled primarily by Macrophage ...
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
... Service includes 1. Scanning of gel(s) ... High-sensitive tryptic in-gel digestion and peptide ... MALDI-MS 5. Acquisition of PMF (Peptide ... ultraflex TOF/TOF) 6. Acquisition of PFF ...
Biology Products: